Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics announced that their Phase 2b trial of RAD 101 in brain metastases achieved its primary endpoint, with 92% of patients showing concordance with MRI imaging. This interim data bolsters confidence in the trial’s success and supports the potential initiation of a pivotal study by the end of 2026. The U.S. market opportunity for RAD 101 is estimated at over $500 million annually, positioning it as a top imaging agent. The trial has reached 50% patient enrollment and has received FDA Fast Track Designation, highlighting its significance in differentiating recurrent disease from treatment effects in brain metastases.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company based in Sydney, Australia. The company focuses on developing innovative oncology radiopharmaceuticals, particularly for areas with high unmet medical needs. Their primary product, RAD 101, is a novel imaging agent designed to target fatty acid synthase for diagnosing brain metastases from various solid tumors.
Average Trading Volume: 6,262,922
Technical Sentiment Signal: Sell
Current Market Cap: A$67.34M
For an in-depth examination of RAD stock, go to TipRanks’ Overview page.